



Commercial/Healthcare Exchange PA Criteria

Effective: May 8th, 2019

Prior Authorization: Calquence

Products Affected: Calquence (acalabrutinib) oral capsule

Medication Description:

Calquence is indicated to treat mantle cell lymphoma (MCL) in adults who have received at least one prior therapy. Calquence inhibits Bruton tyrosine kinase (BTK), which is a signaling molecule with subsequent downstream effects on B-cell proliferation, differentiation, apoptosis, and cell migration.

Covered Uses:

1. Treatment of mantle cell lymphoma in adults who have received at least one prior therapy
2. Treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)

Exclusion Criteria:

1. Pediatric patients less than 18 years of age
2. Previous treatment with a BTK inhibitor (Imbruvica)

Required Medical Information:

1. Diagnosis
2. History of previous therapy tried/failed
3. Dose and frequency

Age Restrictions: 18 years of age and older

Prescriber Restrictions: Prescribed by, or in consultation with, an oncologist

Coverage Duration: 3 years

Other Criteria:

Mantle Cell Lymphoma

- A. Patient has a diagnosis of mantle cell lymphoma
- B. Has received at least one prior therapy (chemotherapy, rituximab, Revlimid, etc); AND
- C. Calquence must be used as a single agent

Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Leukemia (SLL)

- A. Patient has a diagnosis of chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL)

References:

1. Calquence [package insert] Wilmington DE; AstraZeneca; October 2017.
2. Zelenetz AD, Gordon LI, Wierda WG, et al. National Cancer Comprehensive Network (NCCN) clinical practice guidelines in oncology. B cell lymphomas. Available at: https://www.nccn.org/professionals/physician_gls/pdf/Bcell.pdf. Accessed December 14, 2017.

Last Res. December 12th, 2019



Confidential Information

This document is confidential and proprietary to ConnectiCare. Unauthorized use and distribution are prohibited.

3. Micromedex® 2.0 (electronic version). Truven Health Analytics, Greenwood Village, Colorado, USA. Available at: <http://www.micromedexsolutions.com/>. Accessed December 14, 2017.
4. Wu J, Zhang M, Liu D. Acalabrutinib: a selective second-generation BTK inhibitor. J Hematol Oncol. 2016; 9:21. doi: 10.1186/s13045-016-0250-9.

Policy Revision history

Rev #	Type of Change	Summary of Change	Sections Affected	Date
1	New Policy	New Policy, Adopted EH criteria, removed Calquence from CCI "Oncology" Policy	All	4/17/19
2	Policy Update	Added continuation coverage duration of 3 years	Coverage Duration	7/1/2019
3	Policy Update	Updated indication to match FDA Label	Covered Uses, Other Criteria	12/12/2019